Latest news with #Healius
News.com.au
04-06-2025
- Business
- News.com.au
Health Check: Whether stoic or simply too poor, Australians spurn GP visits
Doctor visits dipped in April, reversing a recovery trend Mayne Pharma threatens to go legal in takeover dispute … but peace erupts at Cann Group with settlement of legal spat We're either a healthy lot, rely on Dr Google or simply can't afford to visit a GP anymore. Take your pick as to why our doctor visitations are running below the historic trend. Medicare data for April shows a resumption of a decline in doctors' visits, thus reversing a recent recovery. Bell Potter says the 12-month rolling rate slipped back to 0.8% from 2.3% in March and now is below the long-term median 1.4% growth. In April last year, the rolling rate had dipped to -3%. The slippage was most apparent in Queensland, which shows what stoic souls they are up north. Or maybe they couldn't get to their clinics because they were hemmed in by floods. The rate of doctors' visits has a direct impact on diagnostic imaging volumes and thus is relevant for stocks such as Sonic Healthcare (ASX:SHL), Integral Diagnostics (ASX:IDX), Healius (ASX:HLS) and Australian Clinical Labs (ASX:ACL). (Healius sold its 69 medical centres to private equity firm BGH Capital for $500 million in November 2020.) Macquarie Equities says both pathology and imaging volumes grew 4% in April, year on year. But the DI providers look to be protected by more expensive procedures – 'higher fee modalities', as the firm puts it – with benefits paid rising 8% in April for pathology and 7% for imaging. On the bright side, face-to-face GP visits have held up relative to telehealth and the former is likely to result in diagnostic referrals. So it's a bit of a mixed picture. The re-elected Albo's pledge to extend bulk billing might also ramp up volumes. What will restrain the pain at Mayne? Mayne Pharma's (ASX:MYX) takeover is in the balance, with a 10-day consultation period expiring without suitor Cosette Pharmaceuticals pulling the plug. Cosette alleged that events had resulted in a 'material adverse change', thus triggering the consultation period. Mayne denies these events were material. The FDA has accused Mayne Pharma of downplaying the risks of its oral birth control pill, Nextstellis. Mayne Pharma now says the agency is satisfied the company has addressed the identified issues. Mayne is also in a tat-for-tat legal dispute with the Nasdaq-listed Therapeutics MD, relating to Mayne's purchase of assets from the latter in 2022. While Cosette is yet to walk, the terms of the scheme implementation deed (SID) enable the suitor to do so any time up to the second court hearing to approve the deal. The affair may end up in the courts in a different way, given Mayne 'intends to take all reasonable steps to enforce its rights under the SID.' This includes litigation, of course. Mayne shares this morning surged 5%, but they remain 32% below Cosette's $7.40 a share cash offer. So investors are saying the deal might have a pulse, but not at the original offer price. Cann Group pots legal settlement Medical cannabis play Cann Group (ASX:CAN) has settled a legal dispute with the NZ-listed Rua Biosciences, which had sued a Cann subsidiary over a manufacturing and supply agreement. As is the norm, the agreement is confidential but doesn't involve any money changing hands. Instead, the parties have agreed that Cann will supply 'certain medicinal cannabis products' to Rua under 'agreed market standard commercial terms.' As far as legal spats go, it sounds like a reasonable result. Across the Tasman, Rua shares were up more than 7% this morning Cann shares were about 3% off the pace, having lost 65% of their value year to date. The first Australian company to receive an Australian cannabis research and cultivation licence, Cann produces from its modern Mildura facility. But in the current oversupplied market, it's not easy being green. Radiopharm tackles HER-2 cancers Radiopharm Theranostics (ASX:RAD) has dosed the first patient in its phase I trial to treat advanced HER2-positive solid tumours. A human epidermal growth factor receptor, HER2 is expressed in a variety of tumours including some breast cancers. Dubbed Heat, the study road tests Radiopharm's lutetium isotope-based therapy. Taking place at multiple local centres, the study has the usual safety and tolerability remits. It also aims for the optimal dosage for a phase II trial, as well as early efficacy signals. 'Despite progressive improvements in the management of metastatic HER2-positive disease, the majority of patients experience disease progression on current standard of care and require further therapeutic options,' Radiopharm CEO Riccardo Canevari says. On Monday, the company said preclinical data from another program showed 'favorable biodistribution and ... maintained tumor uptake.' This one refers to its lutetium-based monoclonal antibody RV01, which targets solid tumours expressing the B7H3 protein. This one is via a joint venture with Houston's MD Anderson Cancer Center to develop at least four radiopharmaceutical products. The next step is FDA assent to run a first-in-human trial, which the company hopes to kick off in 2026.
Yahoo
30-04-2025
- Business
- Yahoo
Investors in Healius (ASX:HLS) have unfortunately lost 63% over the last three years
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But long term Healius Limited (ASX:HLS) shareholders have had a particularly rough ride in the last three year. Regrettably, they have had to cope with a 67% drop in the share price over that period. On the other hand the share price has bounced 6.6% over the last week. The buoyant market could have helped drive the share price pop, since stocks are up 3.3% in the same period. Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Because Healius made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually desire strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. Over the last three years, Healius' revenue dropped 11% per year. That's not what investors generally want to see. With revenue in decline, and profit but a dream, we can understand why the share price has been declining at 19% per year. Having said that, if growth is coming in the future, now may be the low ebb for the company. We don't generally like to own companies that lose money and can't grow revenues. But any company is worth looking at when it makes a maiden profit. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So we recommend checking out this free report showing consensus forecasts We'd be remiss not to mention the difference between Healius' total shareholder return (TSR) and its share price return. The TSR attempts to capture the value of dividends (as if they were reinvested) as well as any spin-offs or discounted capital raisings offered to shareholders. Healius' TSR of was a loss of 63% for the 3 years. That wasn't as bad as its share price return, because it has paid dividends. We're pleased to report that Healius shareholders have received a total shareholder return of 27% over one year. There's no doubt those recent returns are much better than the TSR loss of 6% per year over five years. This makes us a little wary, but the business might have turned around its fortunes. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 1 warning sign we've spotted with Healius . Healius is not the only stock insiders are buying. So take a peek at this free list of small cap companies at attractive valuations which insiders have been buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
20-03-2025
- Business
- Yahoo
With 74% institutional ownership, Healius Limited (ASX:HLS) is a favorite amongst the big guns
Given the large stake in the stock by institutions, Healius' stock price might be vulnerable to their trading decisions 52% of the business is held by the top 7 shareholders Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company If you want to know who really controls Healius Limited (ASX:HLS), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with 74% ownership. Put another way, the group faces the maximum upside potential (or downside risk). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Therefore, a good portion of institutional money invested in the company is usually a huge vote of confidence on its future. Let's take a closer look to see what the different types of shareholders can tell us about Healius. See our latest analysis for Healius Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. We can see that Healius does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Healius, (below). Of course, keep in mind that there are other factors to consider, too. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. We note that hedge funds don't have a meaningful investment in Healius. Perpetual Limited is currently the largest shareholder, with 9.8% of shares outstanding. Tanarra Capital Australia Pty Ltd is the second largest shareholder owning 9.4% of common stock, and Spheria Asset Management Pty Ltd holds about 8.6% of the company stock. On further inspection, we found that more than half the company's shares are owned by the top 7 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones. While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our most recent data indicates that insiders own less than 1% of Healius Limited. It has a market capitalization of just AU$966m, and the board has only AU$2.7m worth of shares in their own names. Many investors in smaller companies prefer to see the board more heavily invested. You can click here to see if those insiders have been buying or selling. With a 15% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Healius. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. With a stake of 9.4%, private equity firms could influence the Healius board. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public. While it is well worth considering the different groups that own a company, there are other factors that are even more important. I always like to check for a history of revenue growth. You can too, by accessing this free chart of historic revenue and earnings in this detailed graph. Ultimately the future is most important. You can access this free report on analyst forecasts for the company. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
31-01-2025
- Business
- Yahoo
Undervalued Small Caps With Insider Activity On ASX For January 2025
The Australian market has recently seen the ASX200 reach a record high, buoyed by positive sentiment as concerns over potential tariffs on China ease, with sectors like IT and Materials leading the charge. In this context of shifting investor confidence and sector performance, identifying promising small-cap stocks involves looking at those with strong fundamentals and recent insider activity, which may signal potential opportunities amidst broader market trends. Name PE PS Discount to Fair Value Value Rating Rural Funds Group 7.6x 5.6x 38.60% ★★★★★★ Collins Foods 17.6x 0.6x 8.62% ★★★★★☆ SHAPE Australia 15.3x 0.3x 26.25% ★★★★☆☆ Dicker Data 19.4x 0.7x -62.07% ★★★★☆☆ Abacus Group NA 5.3x 29.32% ★★★★☆☆ Healius NA 0.6x 4.96% ★★★★☆☆ Abacus Storage King 11.1x 6.9x -21.95% ★★★☆☆☆ Autosports Group 5.6x 0.1x -47.17% ★★★☆☆☆ Integral Diagnostics NA 2.5x 49.45% ★★★☆☆☆ Tabcorp Holdings NA 0.7x -10.85% ★★★☆☆☆ Click here to see the full list of 21 stocks from our Undervalued ASX Small Caps With Insider Buying screener. Below we spotlight a couple of our favorites from our exclusive screener. Simply Wall St Value Rating: ★★★★☆☆ Overview: Healius operates in the healthcare sector, providing pathology and imaging services, with a market capitalization of A$2.34 billion. Operations: Healius generates revenue primarily from its Pathology and Imaging segments, with Pathology contributing significantly more than Imaging. The company's cost of goods sold (COGS) has been substantial, affecting its gross profit margin, which has shown a declining trend from 46.25% in early 2014 to around 31.00% by mid-2025. Operating expenses have remained a notable part of the financial structure, impacting overall profitability as seen in varying net income margins over the periods analyzed. PE: -1.6x Healius, a company known for its healthcare services in Australia, recently appointed Kathy Ostin as an independent Non-Executive Director, enhancing their board's expertise in finance and governance. The company's earnings are forecasted to grow by 96% annually, indicating potential value growth. Despite relying solely on external borrowing for funding—considered higher risk—their strategic leadership changes and shareholder-approved constitutional amendments may position them well for future growth. Take a closer look at Healius' potential here in our valuation report. Understand Healius' track record by examining our Past report. Simply Wall St Value Rating: ★★★☆☆☆ Overview: Integral Diagnostics operates diagnostic imaging facilities, providing medical imaging services with a market cap of A$1.19 billion. Operations: Integral Diagnostics generates its revenue primarily from operating diagnostic imaging facilities, with a recent revenue figure of A$469.70 million. The company's gross profit margin was 32.34%, while net income has shown a negative trend, with the latest net income margin at -12.92%. Operating expenses and non-operating expenses have been significant cost factors impacting overall profitability. PE: -19.1x Integral Diagnostics, with its focus on diagnostic imaging services in Australia, presents an intriguing opportunity within the smaller capitalization space. Despite facing challenges like higher risk funding due to reliance on external borrowing and recent shareholder dilution, the company shows potential for growth with earnings projected to rise by 54% annually. Insider confidence is evident as executives have increased their shareholdings recently. The addition of experienced directors like Laura McBain and Dr Kevin Shaw further strengthens its leadership team. Click to explore a detailed breakdown of our findings in Integral Diagnostics' valuation report. Evaluate Integral Diagnostics' historical performance by accessing our past performance report. Simply Wall St Value Rating: ★★★☆☆☆ Overview: K&S is a logistics and transportation company operating primarily in Australia and New Zealand, with a market cap of A$ 0.35 billion, focusing on fuel distribution and transport services across these regions. Operations: K&S generates revenue primarily from Australian Transport and Fuel, with a smaller contribution from New Zealand Transport. The company's gross profit margin has shown fluctuations, peaking at 44.83% before declining to 12.57%, and then rising again to 15.64%. Operating expenses are a significant cost component, including depreciation and amortization expenses that have varied over time but remain substantial in the overall expense structure. PE: 16.0x K&S, an Australian company known for its transport and logistics services, is catching attention in the market due to its perceived undervaluation. Despite having 100% of its liabilities from external borrowing, which presents higher risk compared to customer deposits, insider confidence has been evident with recent share purchases throughout 2024. This insider activity suggests a belief in potential growth or resilience within the industry. As K&S navigates these financial dynamics, investors may find opportunities amidst the challenges. Click here and access our complete valuation analysis report to understand the dynamics of K&S. Examine K&S' past performance report to understand how it has performed in the past. Click here to access our complete index of 21 Undervalued ASX Small Caps With Insider Buying. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:HLS ASX:IDX and ASX:KSC. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
